Loading...
XSHE
300003
Market cap3.26bUSD
Jul 10, Last price  
12.30CNY
1D
2.59%
1Q
-25.23%
Jan 2017
-31.40%
IPO
6.40%
Name

Lepu Medical Technology Beijing Co Ltd

Chart & Performance

D1W1MN
XSHE:300003 chart
P/E
23.57
P/S
3.50
EPS
0.52
Div Yield, %
2.48%
Shrs. gr., 5y
0.74%
Rev. gr., 5y
-4.21%
Revenues
6.48b
+6.22%
175,338,190298,984,733393,879,358565,197,407770,100,945909,571,1841,015,920,0791,303,267,8311,668,636,9552,768,717,4633,467,748,2334,537,642,6566,356,304,7917,795,529,3858,038,667,54010,659,734,87410,609,442,0807,979,899,3186,103,269,1056,482,731,703
Net income
962m
+289.57%
63,600,462149,725,515201,368,062292,212,135410,482,721473,157,671403,273,294361,645,478423,192,557520,890,611679,255,742899,085,3391,218,692,9071,725,306,1961,801,932,5351,719,324,5842,203,779,3781,258,200,343246,937,718962,006,332
CFO
1.52b
+106.48%
58,317,51961,365,102188,594,285239,785,236374,248,775291,197,594264,962,979329,757,071348,316,884436,460,676691,890,147913,132,5411,500,508,9371,990,255,0632,089,699,3043,061,991,8512,790,709,307990,359,814734,643,8891,516,920,676
Dividend
Sep 23, 20250.16275 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in 1999 and headquartered in Beijing, China, Lepu Medical Technology is a prominent company dedicated to the research, development, production, and sale of a broad spectrum of medical devices, pharmaceuticals, and healthcare services. The company's extensive medical device portfolio primarily focuses on cardiovascular health. This includes interventional cardiology products such as coronary stents, balloons, catheters, guide wires, and related PCI accessories. It also provides solutions for structural heart diseases, like occluders, vascular plugs, delivery systems, and mechanical heart valves. Lepu Medical offers cardiac rhythm management products, including pacemakers, equipment, leads, and electrophysiology systems, alongside products for off-pump coronary artery bypass grafting and peripheral interventional devices such as PTA balloons and guide wires. Beyond cardiovascular applications, their offerings extend to critical care products like vascular access devices, needle-free connectors, blood samplers, and pressure transducers. The company also provides digital subtraction angiography (DSA) systems (both floor and suspended types), in vitro diagnostic (IVD) equipment and biomarkers, hemodialysis catheters and hollow fiber dialyzers, and general surgery instruments including surgical staplers and endo surgery accessories. In the pharmaceutical sector, Lepu Medical manufactures and distributes medications for various conditions. This encompasses a comprehensive range of cardiovascular drugs designed to treat issues like thrombosis, hyperlipidemia, hypertension, angina, and heart failure. Additionally, they produce beta-lactamase antibiotics and antifungal antimicrobial drugs, central nervous system medications (such as painkillers and antidepressants), treatments for gastric/duodenal ulcers and chronic liver disease, respiratory system drugs, hypoproteinemia drugs, and agents that activate blood circulation. Furthermore, Lepu Medical provides a diverse array of healthcare services. These include precision medicine, remote ECG telemonitoring, and specialized consulting and management centers for cardiovascular diseases. The company is also involved in medical science and technology incubation, equity investment, and offers medical financial services. Its service offerings extend to general health consultation, online pharmacy platforms, sales of household medical equipment, smart medical devices, and the operation of specialized hospitals focusing on cardiovascular care. Lepu Medical actively participates in the establishment and co-construction of cardiac catheterization laboratories (Cath Labs).
IPO date
Oct 30, 2009
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT